Necl-5 is an immunoglobulin (Ig)-like molecule that was originally identified as a poliovirus receptor and is often upregulated in cancer cells. We recently found that it colocalizes with integrin a v b 3 at the leading edges of moving cells and enhances growth factor-induced cell movement and proliferation. Upon cell-cell contact, Necl-5 is removed from the cell surface by its trans-interaction with the cell adhesion molecule nectin-3, resulting in reduced cell movement and proliferation. Here, we investigated the role of Necl-5 in the interaction of cancer cells with platelets. Necl-5 was upregulated in CT26 cells, a colon adenocarcinoma cell line. When CT26 cells were injected into the tail vein of mice, they were arrested in the pulmonary vessels by adhering to platelets and subsequently metastasized to the lungs. Overexpression of Necl-5 in CT26 cells enhanced this metastasis, while inhibition of the trans-interaction of Necl-5 with CD226 by an anti-Necl-5 monoclonal antibody reduced the metastasis. Depletion of platelets by treatment with a rabbit anti-mouse platelet serum reduced the Necl-5-enhanced metastasis in mice. Thus, the trans-interaction of upregulated Necl-5 in cancer cells with its counterreceptor in platelets, probably CD226, is critical for efficient metastasis of cancer cells to the lungs.
Introduction
The characteristics of malignant cancer cells are abnormal proliferation, invasion into the surrounding tissues and metastasis to other organs (Thiery, 2002) . Many oncogenes and suppressor genes have been identified and their modes of action in normal cell proliferation and as well as the modes of action of their mutations, suppression or augmentation in abnormal cell proliferation are fairly well established. In contrast, disruption of cell-cell adhesion, enhanced cell movement and loss of contact inhibition of cell movement and proliferation are involved in the invasiveness and metastasis of cancer cells, but the mechanisms for how mutations and modifications of oncogenes and tumor suppressor genes cause these pathological events are poorly understood.
We recently found that an immunoglobulin (Ig)-like molecule, Necl-5/poliovirus receptor (PVR)/CD155/ Tage4, colocalizes with integrin a v b 3 at the leading edges of moving cells and enhances growth factorinduced cell movement and proliferation Kakunaga et al., 2004) . Human PVR/CD155 was originally identified as a PVR (Mendelsohn et al., 1989; Koike et al., 1990) , while rodent Tage4 was originally identified as the product of an overexpressed gene in rodent colon carcinoma (Chadeneau et al., 1994) . PVR/ CD155 is also overexpressed in many human cancer cells (Gromeier et al., 2000; Masson et al., 2001 ). This molecule with four nomenclatures has tentatively been designated nectin-like molecule-5, Necl-5 (Takai et al., 2003) . Integrin a V b 3 is often upregulated in cancer cells and appears to be involved in their invasiveness and metastasis (Guo and Giancotti, 2004) .
The modes of action of Necl-5 in cell movement and proliferation have been elucidated. Specifically, Necl-5 enhances growth factor-induced activation of Cdc42 and Rac small G proteins, causing the formation of filopodia and lamellipodia, respectively, which eventually enhances cell movement . The cytoplasmic region of Necl-5 binds to Tctex-1, a subunit of the dynein motor complex, which may also be involved in regulating cell movement in cooperation with microtubules (Mueller et al., 2002) . Necl-5 enhances the activation of Ras-Raf-MEK-ERK signaling, and induces upregulation and downregulation of cell cycle regulators, including cyclins D2 and E, and p27 kip1 , thereby shortening the period of the G 1 phase of the cell cycle . Necl-5 is upregulated in NIH3T3 cells transformed by the oncogene V12-Ki-Ras and this upregulation is mediated by transcriptional activation of the Necl-5 gene through the V12-Ki-RasRaf-MEK-ERK-AP-1 pathway (Hirota et al., 2005) .
Necl-5 does not show any homophilic cell-cell adhesion activity, but does heterophilically trans-interact with nectin-3, a member of the Ig-like nectin family that acts as a Ca 2 þ -independent cell-cell adhesion molecule and forms adherens junctions cooperatively with cadherins Takai et al., 2003) . When cells come into contact with other cells, Necl-5 is downregulated from the cell surface by its transinteraction with nectin-3 (Fujito et al., 2005) . However, when cells do not come into contact with other cells, Necl-5 is upregulated at the transcriptional level by growth factor-induced signaling (Hirota et al., 2005) . Upregulation of Necl-5 enhances growth factor-induced cell movement and proliferation, whereas downregulation of Necl-5 reduces them (Fujito et al., 2005) . Cultured normal cells continue to move until they come into contact with other cells and become confluent. They then undergo cell-cell adhesion and stop moving. This phenomenon has been known for more than 50 years as contact inhibition of cell movement and proliferation (Abercrombie and Heaysman, 1953; Abercrombie, 1979) . This contact inhibition is lost when normal cells are transformed. We previously proposed that Necl-5 plays a role, at least in part, in this contact inhibition of cell movement (Fujito et al., 2005) .
These biological properties of Necl-5 suggest that its upregulation in many cancer cells plays a role in their metastasis. The metastasis of cancer cells consists of multiple steps: (1) disruption of cell-cell adhesion and enhancement of cell movement, (2) invasion into the surrounding tissues, (3) entry into blood/lymph vessels, (4) transport to other organs, (5) arrest in the vessels, (6) exit from the vessels and (7) proliferation there (Thiery, 2002) . Among these steps, we examined steps (5)- (7) by injecting cancer cells into the tail vein of mice and measuring metastasis to the lungs. We found that the upregulated Necl-5 in cancer cells transinteracts with its counter-receptor in platelets, probably CD226, and that this trans-interaction enhances the metastasis of the cancer cells. CD226, also called DNAM-1, is another Ig-like molecule and was originally identified as a DNAX accessory molecule (Shibuya et al., 1996) . CD226 is expressed on the majority of peripheral blood T lymphocytes, and also on platelets (Kojima et al., 2003) . On the other hand, platelets are involved in the metastasis of cancer cells (Nash et al., 2002) . When cancer cells enter blood vessels, platelets attach to the cells and the resulting aggregates of platelets and cancer cells arrest the cancer cells in a blood vessel and then induce extravasation of cancer cells. Although the formation of these aggregates is well accepted, the detailed mechanisms of the interaction between platelets and cancer cells remain unknown. Therefore, it is important to clarify the mechanisms of the interaction between platelets and cancer cells to understand the metastasis of cancer cells and develop therapies for preventing this metastasis. Here, we describe a role of Necl-5 in the metastasis of cancer cells to the lungs.
Results
Enhancement of metastasis of cancer cells to the lungs by Necl-5 Necl-5 has been shown to be upregulated in many types of cancer cells (Chadeneau et al., 1994 (Chadeneau et al., , 1996 Gromeier et al., 2000; Masson et al., 2001; Sloan et al., 2004) . We used fluorescent-activated cell sorting (FACS) analysis to examine the expression levels of cell surface Necl-5 in various cancer cell lines, namely CT26, Colon 26, B16F1, Meth A and OVHM. Necl-5 was strongly expressed in all of these cancer cell lines (Figure 1a) .
To evaluate the metastatic potential of Necl-5 on cancer cells, CT26 cells, a colon adenocarcinoma cell line, were infected with a retroviral supernatant generated by transfecting pMX-Necl-5 into packaging cells. Puromycin-resistant CT26 cells were established and designated Necl-5-CT26 cells. FACS analysis revealed that the expression level of surface Necl-5 was about 10-fold higher in Necl-5-CT26 cells than in parental CT26 cells and control pMX-CT26 cells infected with a retroviral supernatant using the pMX vector alone ( Figure 1b) . Next, we compared the rates of metastasis to the lungs among wild-type CT26, Necl-5-CT26 and pMX-CT26 cells. We injected each cell line into the tail vein of BALB/c mice and counted the numbers of tumor nodules in the lungs. The sizes of the lungs containing metastasized Necl-5-CT26 cells were larger than those containing metastasized CT26 and pMX-CT26 cells (Figure 1c ). The number of metastatic foci in the lungs of mice receiving Necl-5-CT26 cells was 175740 and four-to sevenfold higher than those in the lungs of mice receiving CT26 cells (2476) or pMX-CT26 cells (46716; Figure 1d ). Histological examination revealed that the metastasized Necl-5-CT26 cells in the lungs formed large foci beneath the veins (Figure 1e ). These results suggest that Necl-5 enhances metastasis of CT26 cells to the lungs.
We subsequently used another cancer cell line, the OVHM ovarian cancer cell line, to further examine the potential effect of Necl-5 on metastasis. The number of Necl-5-overexpressing OVHM cells (Necl-5-OVHM cells) that metastasized to the lungs was 356711 and about 10-fold higher than the numbers of metastasized parental OVHM cells (1177) and control pMX-OVHM cells introducing the pMX vector alone (270.5) ( Supplementary Figures 1a-d) . These results demonstrate that Necl-5 augments the metastasis of cancer cells of different organ origins to the lungs.
Inhibition of cancer metastasis by an anti-Necl-5 monoclonal antibody Next, we analysed the effects of an anti-Necl-5 monoclonal antibody (mAb) on cancer metastasis to the lungs using CT26 cells. This mAb inhibits the trans-interaction of Necl-5 with nectin-3 . BALB/c mice were injected i.v. with CT26 cells treated with the anti-Necl-5 mAb, or with phosphate-buffered saline (PBS) or rat immunoglobulin G (IgG) as controls. The animals were killed on day 14 and the tumor nodules on the surface of their lungs were counted. The apparent lung size was smaller in mice injected with CT26 cells treated with the anti-Necl-5 mAb than in control mice treated with PBS or IgG (Figure 2a ). The number of tumor nodules formed by CT26 cells treated with the anti-Necl-5 mAb was reduced to one-third of the number formed by control CT26 cells treated with PBS or IgG (Figure 2b ). These results provide another line of evidence that Necl-5 is involved in the metastasis of cancer cells to the lungs.
Next, we analysed the effect of the anti-Necl-5 mAb on tumor growth in the s.c. tissue. BALB/c mice were injected i.v. with the anti-Necl-5 mAb, PBS or rat IgG before and after a s.c. injection of CT26 cells. Tumor growth was measured two to three times per week, and the mean volumes in cubic millimeters were calculated ( Figure 2c ). The animals were killed on day 28 and the tumor volumes were measured ( Figure 2d ). Tumors appeared at day 6 in all three mouse groups, and injection of the anti-Necl-5 mAb had no effect on the tumor size. These results indicate that the anti-Necl-5 mAb does not affect the proliferation of cancer cells in vivo.
Arrest of cancer cells in pulmonary vessels Next, we analysed how cancer cells are metastasized to the lungs. To assess the arrest of cancer cells in the lungs, we injected carboxyfluorescein diacetate-succinimidyl ester (CFSE)-labeled CT26, pMX-CT26 and Necl-5-CD226 interaction in lung metastasis K Morimoto et al Necl-5-CT26 cells into the tail vein of mice and collected the lung tissue at 24 h after the injection. Clusters of CFSE-labeled CT26 and pMX-CT26 cells were observed inside the capillaries (Figure 3a ). It should be noted that Necl-5-CT26 cells were also observed around the capillaries. Quantitative analysis revealed that the number of arrested cells was twofold higher for Necl-5-CT26 cells (86721) than for CT26 cells (43717) or pMX-CT26 cells (45711; Figure 3b ). These results suggest that Necl-5 plays a role in the lodgment of cancer cells in the pulmonary vessels during the early stages of metastasis.
Arrest of cancer cells in pulmonary vessels by Necl-5-dependent attachment to CD226-expressing platelets Necl-5 has been shown to heterophilically trans-interact with CD226 (Bottino et al., 2003) and nectin-3 . CD226 is an Ig-like cell-cell adhesion molecule with two Ig-like loops in the extracellular region (Shibuya et al., 1996) . First, we examined whether immunofluorescence signals for CD226 and nectin-3 were detected at sites surrounding CT26 cells arrested in the lungs. Immunofluorescence microscopy revealed that signals for CD226, but not nectin-3, were 6 CFSE-labeled CT26 cells were killed after 24 h, and their lungs were isolated. Samples were double stained with various combinations of anti-CD226, anti-CD41 and anti-Necl-5 mAbs. Bars, 10 mm. (e) Depletion of platelets. BALB/c mice were injected i.p. with a rabbit anti-mouse platelet serum and the numbers of platelets and white blood cells were monitored. (f) Role of platelets in Necl-5-induced metastasis. Untreated or anti-platelet serum-pretreated BALB/c mice (n ¼ 6) were injected i.v. with 1 Â 10 6 CT26 or Necl-5-CT26 cells. The mice were killed after 24 h, and their lungs were isolated. Samples were double-stained with antiNecl-5 mAb and 4,6-diamidino-2-phenyl indole. The number of Necl-5-positive cancer cells in a determined area of the surface was counted as described in the 'Materials and methods'.
Necl-5-CD226 interaction in lung metastasis
K Morimoto et al concentrated at sites surrounding CT26 cells ( Figure 4a ). Next, we examined whether the anti-Necl-5 mAb inhibits the trans-interaction of Necl-5 with CD226, nectin-3 or both. We plated B300-19 cells expressing CD226 or nectin-3 onto dishes, which were precoated with the extracellular region of Necl-5 fused to alkaline phosphatase (Necl-5-AP), in the presence or absence of the anti-Necl-5 mAb, washed the cells and then counted the numbers of cells that attached to the dishes. B300-19 cells expressing either CD226 or nectin-3 adhered to the dishes, and their adhesion to Necl-5-AP was efficiently inhibited by the anti-Necl-5 mAb (Figure 4b) . It has been shown that CD226 is expressed in platelets (Kojima et al., 2003) , and that platelets play important roles in thrombosis and the induction of tumor metastasis. We used FACS analysis to confirm that CD226 was expressed in platelets, and that expression of nectin-3 or Necl-5 was not detected (Figure 4c ). Immunofluorescence microscopy revealed that signals for CD226 as well as a platelet marker, CD41, were concentrated in the cells, presumably platelets that surrounded CT26 cells (Figure 4d) . Furthermore, the signals for CD226 roughly colocalized with those of Necl-5, which was expressed in CT26 cells. These results suggest that adhesion of CT26 cells to platelets through the trans-interaction of Necl-5 with CD226 is involved in the lung metastasis of CT26 cells.
To further confirm the role of platelets in the Necl-5-enhanced metastasis, BALB/c mice were depleted of platelets by treatment with a rabbit anti-mouse platelet serum. Peripheral blood platelets were selectively decreased to o5% of the normal level from 6 to 48 h after the serum injection without any drastic reduction in the white blood cells (Figure 4e) . Next, CFSE-labeled pMX-CT26 and Necl-5-CT26 cells were injected into Necl-5-CD226 interaction in lung metastasis K Morimoto et al mice at 6 h after the anti-platelet serum treatment. Depletion of platelets significantly suppressed the pulmonary attachment of cancer cells (Figure 4f ). The mean number of arrested pMX-CT26 and Necl-5-CT26 cells decreased from 4178 to 1475 and from 117714 to 2478, respectively, in the platelet-depleted mice. These results suggest that platelets predominantly mediate Necl-5-dependent tumor cell attachment to pulmonary vessels.
Necl-5 is a major platelet adhesion molecule that trans-interacts with CD226
We further confirmed that Necl-5 is a major cell-cell adhesion molecule of CT26 cells that trans-interacts with its counter-receptor of platelets. Adhesion between CT26 cells and platelets was inhibited by the antiNecl-5 mAb, suggesting that Necl-5 is involved in the adhesion (Figure 5a ). CD226 has also been shown to trans-interact with nectin-2 (Bottino et al., 2003) . Furthermore, nectin-2 and Necl-5 are both expressed in various tumor cell lines (Bottino et al., 2003) . We detected nectin-2 expression in CT26 cells by FACS analysis (Figure 5b ). We then examined whether Necl-5 on CT26 cells is the major CD226 counter-receptor. To achieve this, we prepared an anti-nectin-2 mAb that inhibited the trans-interaction of nectin-2 with CD226. This mAb inhibited the attachment of CD226-expressing B300-19 cells to dishes precoated with the extracellular region of nectin-2 fused to alkaline phosphatase (nectin-2-AP; Figure 5c ). The interaction between CT26 cells and CD226-AP was not significantly reduced by the anti-nectin-2 mAb alone, but was markedly inhibited by the anti-Necl-5 mAb alone or a mixture of the anti-Necl-5 and anti-nectin-2 mAbs (Figure 5d ). These results indicate that Necl-5 is a major cell-cell adhesion molecule of CT26 cells that trans-interacts with CD226.
Discussion
Necl-5 is upregulated in many types of human and rodent cancer cells (Chadeneau et al., 1994 (Chadeneau et al., , 1996 Gromeier et al., 2000; Masson et al., 2001; Sloan et al., 2004) . We further confirmed upregulation of Necl-5-CD226 interaction in lung metastasis K Morimoto et al Necl-5 in several cancer cell lines, including CT26, Colon 26, B16F1, Meth A and OVHM. The physiological and pathological roles of this upregulated Necl-5 are unknown, although we found that it enhances cell movement and proliferation. In the present study, we have shown that Necl-5 enhances cancer cell metastasis to the lungs. Among the multiple steps involved in cancer cell metastasis to the lungs, we have demonstrated that upregulated Necl-5 is involved in at least the steps of arrest in the lungs, exit from the vessels and proliferation in the lungs, although it still remains unknown whether the upregulated Necl-5 is involved in the initial steps of metastasis, such as invasion to surrounding tissues and entry into blood and lymph vessels. We initially anticipated that disruption of the trans-interaction of Necl-5 with nectin-3 by an antiNecl-5 mAb would lead to enhanced metastasis of cancer cells to the lungs, since this trans-interaction reduces cell movement and proliferation. Unexpectedly, however, we found that this mAb reduced cancer cell metastasis to the lungs. Our subsequent detailed experiments revealed that the upregulated Necl-5 in cancer cells trans-interacts with a counter-receptor other than nectin-3, probably CD226, in platelets and that this trans-interaction enhances the metastasis of the cancer cells. Platelets play an important role in thrombosis and are also involved in the induction of inflammation, tissue repair and tumor metastasis. The adhesive interaction between cancer cells and platelets has been reported to play a critical role in metastasis (Nash et al., 2002) . However, the molecules that facilitate the arrest of cancer cells in blood vessels have not yet been fully identified. We have shown that Necl-5 on cancer cells and a counter-receptor other than nectin-3, probably CD226, on platelets are important cell-cell adhesion molecules involved in the adhesion between cancer cells and platelets in vitro as well as in pulmonary metastasis in vivo. It was previously reported that association of melanoma cells with adherent thrombi results in stable arrest under in vitro flow conditions and that inhibition of platelet activation, platelet integrin a IIb b 3 or melanoma integrin b 3 function abolishes the cell attachment (Felding-Habermann et al., 1996) . In vivo, association of platelets with tumor cells attached to the vascular endothelium has been reported (Crissman et al., 1988) , suggesting that platelets may stabilize and protect attached tumor cells during blood flow. Consistent with this hypothesis, we found that CD226 þ /CD41 þ platelets surrounded CT26 cells arrested in the pulmonary vasculature and that signals for CD226 colocalized with those of Necl-5 on CT26 cells. Furthermore, depletion of platelets, but not leukocytes, significantly suppressed the pulmonary attachment of cancer cells. These results clearly show that platelets predominantly mediate Necl-5-dependent tumor cell attachment to pulmonary vessels probably through the trans-interaction of Necl-5 with CD226.
Beyond the physical interaction between cancer cells and platelets, it is tempting to speculate that these molecules also enhance metastasis by activating platelets as well as increasing the cell motility and proliferation of cancer cells. CD226 was originally identified as a signaltransducing adhesion molecule involved in the cytolytic function mediated by cytolytic T lymphocytes and natural killer (NK) cells. Initiation of the cytotoxicity function by cross-linking of the CD226 receptor depends upon its Ser329 phosphorylation by protein kinase C (PKC) and physical and functional interactions with LFA-1 (Shibuya et al., 1999) . CD226 is also known as platelet and T-cell antigen 1 and its cross-linking by a mAb stimulates platelet secretion and activation in a PKC-dependent manner (Sherrington et al., 1997) . On the other hand, Necl-5 colocalizes with integrin a v b 3 at the leading edges of moving cells and enhances growth factor-induced cell movement and proliferation by facilitating growth factor-induced activation of Cdc42 and Rac small G proteins Kakunaga et al., 2004) . Necl-5 in glioma cells increases motility and substrate-dependent reductions in adhesion and cell spreading by modulating an adhesion-induced Src/ FAK/paxillin/p130Cas signaling pathway to destabilize focal adhesions at the cell-substrate interface (Sloan et al., 2005) . Thus, the trans-interaction of Necl-5 and CD226 may enhance the lung metastasis by inducing activation signals in both cancer cells and platelets.
In this context, molecules activating both platelets and cancer cells have been shown to promote metastasis. Aggrus/podoplanin is a type-I transmembrane sialomucin-like glycoprotein that induces platelet aggregation and its expression is frequently upregulated in colorectal tumors (Kato et al., 2003) . A mAb against Aggrus inhibited tumor-induced platelet aggregation in vitro as well as the pulmonary metastasis of highly metastatic clones of a mouse colon adenocarcinoma cell line in vivo. Recently, Aggrus was shown to bind ezrin-radixinmoesin proteins to activate RhoA small G protein and promote the epithelial-mesenchymal transition, leading to increased cell migration and invasiveness (MartinVillar et al., 2006) . Im et al. (2004) reported that tumor cells initially make contact with exposed basement membrane, followed by spreading of the tumor on the vessels in a manner that is morphologically reminiscent of cell spreading in vitro. Inhibition of coagulation with a thrombin inhibitor did not alter the association of tumor cells with platelets and fibrin or fibrinogen at the time of early arrest. However, tumor cell spreading at 6-24 h and subsequent retention of tumor cells in the lungs was markedly inhibited by anticoagulant treatment. Thus, tumor cell spreading on the vascular surface constitutes an important component of the metastatic cascade mediated by coagulation. It remains to be seen whether Necl-5 facilitates the platelet-dependent initial attachment, the cell spreading leading to stable arrest in the vessel or both.
Under inflammatory conditions, leukocytes are captured by selectins, activated by chemokines and firmly adhered by integrins on endothelial cells, before finally transmigrating from the blood circulation into the peripheral tissues by passing through the endothelial cell-cell junctions. The multistep adhesion molecule cascade involved in leukocyte trafficking may also regulate the cell adhesion, migration and tissue tropism of cancer cells during tumor metastasis. In this regard, Reymond et al. (2004) reported that CD226 on monocytes interacts directly with Necl-5 at endothelial cell-cell junctions and promotes their transendothelial migration by acting specifically during the diapedesis step. Furthermore, CD226 mediates the adhesion of thrombin-activated, but not resting, platelets to vascular endothelial cells (Kojima et al., 2003) . Considering that cancer cells could be covered with platelets, their adhesion to and diapedesis through endothelial cells may be facilitated indirectly by the platelet-endothelial interaction. Further studies are needed to clarify whether Necl-5 enhances the diapedesis of cancer cells arrested in blood vessels.
In the present study, we have shown that Necl-5 is the major counter-receptor for CD226 on cancer cells, despite the fact that both Necl-5 and nectin-2 are expressed on these cells. Similarly, Necl-5, but not nectin-2, was previously found to be the major CD226 counter-receptor on endothelial cells (Reymond et al., 2004) . These results suggest that the CD226-binding domain of nectin-2 may be in an inactive conformational state in cancer cells as well as in resting endothelial cells. We have further indicated that CD226, but not nectin-3, is a counter-receptor for Necl-5 on platelets. However, CD96/Tactile was recently found to interact with Necl-5 and promote NK cell-target cell adhesion (Fuchs et al., 2004) . Thus, we cannot exclude the possibility that Necl-5 also interacts with CD96 on the platelets in addition to CD226. Further studies by using neutralizing anti-CD226 antibody or CD226 knockout mice are needed to determine whether CD226 is the sole counter-receptor for Necl-5 on platelets.
Materials and methods

See Supplementary Information.
Abbreviations
Necl-5-AP, extracellular region of Necl-5 fused to alkaline phosphatase; nectin-2-AP, extracellular region of nectin-2 fused to alkaline phosphatase; PVR, poliovirus receptor.
